NY-ROHATYN-GROUP
12.5.2020 18:09:09 CEST | Business Wire | Press release
The Rohatyn Group (“TRG”), an emerging markets focused asset management firm, today announced that it has completed an investment in Optimapharm d.d. (“Optimapharm” or the “Company”), to establish a partnership with the company’s founders Gordana Gregurić Čičak and Igor Čičak. Optimapharm is a contract research organization (“CRO”) managing clinical trials on behalf of leading biotech, pharma and medical devices companies in 22 countries throughout Europe.
Founded in 2006 in Croatia, Optimapharm is a full service mid-sized CRO with expertise in managing trials across Europe, providing tailored solutions and offering differentiated access to patients. With premium professional services and competitive costs at high industry standards, the Company has had a repeat business rate of over 95%. With TRG’s investment, Optimapharm will seek to continue to grow both organically and through strategic acquisitions.
“Optimapharm is a highly attractive business that provides a unique offering in the European CRO space, leveraging its roots in South-East Europe. We believe that they are well-positioned for continued growth given the increasing prevalence of clinical trial services outsourcing across many important market segments, including oncology, an area in which they have a particular expertise,” said Colin Clark, TRG’s Head of EMEA Private Markets Investing and TRG Director Harold Chatelus. “CROs are increasingly acting as strategic advisors, actively proposing clinical study design advice and focusing on optimizing processes. We are proud to support the Company’s next chapter as well as the development of innovative treatments by Optimapharm’s clients.”
Nick Rohatyn, CEO of TRG added, “Optimapharm is a high-growth, pan-regional business that fits perfectly with the rest of TRG’s portfolio. We believe strongly that the Company has the potential to be a leading player in the European CRO space thanks to its strong brand and dedication to high-quality service for its blue-chip clients around the world.”
Gordana Gregurić Čičak, founder and CEO, and Igor Čičak, founder and Chairman, commented, ”We are tremendously proud of the growth achieved by the team at Optimapharm, particularly in the last 18 months, which saw a rate of geographic expansion unprecedented in the firm’s history. TRG’s investment will accelerate the next phase in the Company’s development through further regional expansion and bolt-on acquisitions. We look forward to continuing our growth in partnership with The Rohatyn Group and leveraging the team’s expertise.”
About TRG
Founded in 2002, The Rohatyn Group is an emerging markets focused asset management firm headquartered in New York, with offices around the globe including Boston, Singapore, Rotorua, Mumbai, New Delhi, London, Buenos Aires, Montevideo, Lima, and São Paulo. For more information, please visit www.rohatyngroup.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005718/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Expertsin Vienna19.10.2026 12:00:00 CEST | Press release
Data Center World Europe 2027 took place October 13-15 at VIECON – Vienna Congress & Convention Center in Austria Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 12:00:00 CEST | Press release
New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne’s solid tumor pipelineMultiple TEVIMBRA abstracts reinforce breadth of evidence across lung and gastrointestinal cancers, including data in combination with ZIIHERA in HER2+ gastroesophageal cancer BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 11:30:00 CEST | Press release
More than half of ENTYVIO patients who met their assigned treatment target reached disease clearance (composite of corticosteroid-free symptomatic, endoscopic and histologic remission) at Week 16VERDICT is the first trial to provide macroscopic and microscopic evidence of intestinal tissue repair associated with disease clearance in largely bio-naïve patients treated with an advanced therapy Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically rel
Boomi Acquires Elementary Data to Bring Trusted, Governed Data to the AI Era19.10.2026 11:00:00 CEST | Press release
Acquisition adds widely adopted data observability and reliability capabilities to the Boomi Enterprise Platform, giving enterprises the data quality and governance required to operationalize AI Boomi, the data activation company for AI, today announced it has acquired Elementary Data, a provider of the widely adopted data observability solution that powers every workflow and AI agent with reliable data. Following Lunar.dev, Elementary is Boomi’s latest acquisition, strengthening the Boomi Enterprise Platform with the observability, quality, governance, and discovery capabilities enterprises need to deliver trusted data for AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019376249/en/ Boomi Acquires Elementary Data to Bring Trusted, Governed Data to the AI Era Key TakeawaysWhat Boomi acquired. Elementary provides unified observability, quality, governance, and discovery. Founded in 2022, Elementary began as an open-sou
Reply Earns “NVIDIA Physical AI Specialization” for Production-Ready Robotics and Digital Twins19.10.2026 10:00:00 CEST | Press release
Reply [EXM, STAR: REY] is among the first NVIDIA partners in the world to achieve the “Physical AI Specialization” within the NVIDIA Partner Network (NPN), in recognition of its expertise in developing and deploying AI-driven robotics and digital twin solutions for real-world operating environments. The specialization was awarded following a technical assessment covering a customer implementation, solution architecture, certified OpenUSD expertise and Reply’s development roadmap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019881053/en/ Reply is among the first NVIDIA partners in the world to achieve the “Physical AI Specialization” within the NVIDIA Partner Network (NPN), in recognition of its expertise in developing and deploying AI-driven robotics and digital twin solutions for real-world operating environments. Physical AI is becoming increasingly relevant in manufacturing, warehousing and logistics as companies mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom